Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16128286 | 0.91 | FABP5 (0.48) | KMT2ASLC7A5EPHX2FABP5FABP7 | |
| SCHEMBL29392800 | 0.91 | FABP5 (0.48) | KMT2ASLC7A5EPHX2FABP5FABP7 | |
| SCHEMBL29823700 | 0.84 | PPARG (0.39) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL29966663 | 0.81 | KMT2A (0.51) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL15318692 | 0.81 | KMT2A (0.51) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL29510568 | 0.80 | KMT2A (0.47) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL16128277 | 0.80 | CASP3 (0.50) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL14416228 | 0.80 | KMT2A (0.47) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL29823514 | 0.79 | KMT2A (0.46) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL29493719 | 0.78 | SLC7A5 (0.57) | KMT2ASLC7A5HDAC8TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160333050-A1 | NOVEL CROSS-LINKED PEPTIDES CONTAINING NON-PEPTIDE CROSS-LINKED STRUCTURE, METHOD FOR SYNTHESIZING CROSS-LINKED PEPTIDES, AND NOVEL ORGANIC COMPOUND USED IN METHOD | JITSUBO CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
| US-20160333052-A1 | NOVEL CROSS-LINKED PEPTIDES CONTAINING NON-PEPTIDE CROSS-LINKED STRUCTURE, METHOD FOR SYNTHESIZING CROSS-LINKED PEPTIDES, AND NOVEL ORGANIC COMPOUND USED IN METHOD | JITSUBO CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
| US-9376467-B2 | Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method | JITSUBO CO., LTD. (JP) | 2016-06-28 | — | — | US | disclosed |
| US-9365615-B2 | Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method | JITSUBO CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| WO-2016077518-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2015061733-A1 | DIAGNOSTIC METHODS FOR PAR4 ANTAGONIST THERAPY | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2015-04-30 | — | — | WO | disclosed |
| US-20150073121-A1 | NOVEL CROSS-LINKED PEPTIDES CONTAINING NON-PEPTIDE CROSS-LINKED STRUCTURE, METHOD FOR SYNTHESIZING CROSS-LINKED PEPTIDES, AND NOVEL ORGANIC COMPOUND USED IN METHOD | JITSUBO CO., LTD. (JP) | 2015-03-12 | — | — | US | disclosed |
| WO-2014151634-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333050-A1 | NOVEL CROSS-LINKED PEPTIDES CONTAINING NON-PEPTIDE CROSS-LINKED STRUCTURE, METHOD FOR SYNTHESIZING CROSS-LINKED PEPTIDES, AND NOVEL ORGANIC COMPOUND USED IN METHOD | NRDC, VIP, NRP1 | KMT2A 3705/4885SLC7A5 2272/4885EPHX2 865/4885 |
| US-20160333052-A1 | NOVEL CROSS-LINKED PEPTIDES CONTAINING NON-PEPTIDE CROSS-LINKED STRUCTURE, METHOD FOR SYNTHESIZING CROSS-LINKED PEPTIDES, AND NOVEL ORGANIC COMPOUND USED IN METHOD | NRDC, VIP, NRP1 | KMT2A 3705/4885SLC7A5 2272/4885EPHX2 865/4885 |
| US-20150073121-A1 | NOVEL CROSS-LINKED PEPTIDES CONTAINING NON-PEPTIDE CROSS-LINKED STRUCTURE, METHOD FOR SYNTHESIZING CROSS-LINKED PEPTIDES, AND NOVEL ORGANIC COMPOUND USED IN METHOD | NRDC, VIP, NRP1 | KMT2A 3705/4885SLC7A5 2272/4885EPHX2 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.